Ninety One UK Ltd Purchases 480,496 Shares of Edwards Lifesciences Co. (NYSE:EW)

Ninety One UK Ltd raised its stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 2,740.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 498,029 shares of the medical research company's stock after buying an additional 480,496 shares during the period. Ninety One UK Ltd owned 0.08% of Edwards Lifesciences worth $37,975,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Castleview Partners LLC acquired a new stake in Edwards Lifesciences in the first quarter valued at approximately $25,000. Compass Wealth Management LLC acquired a new position in shares of Edwards Lifesciences during the fourth quarter worth $31,000. Turtle Creek Wealth Advisors LLC acquired a new position in Edwards Lifesciences in the fourth quarter valued at $34,000. Jackson Grant Investment Advisers Inc. acquired a new position in Edwards Lifesciences in the third quarter valued at $38,000. Finally, Janiczek Wealth Management LLC lifted its holdings in Edwards Lifesciences by 108.6% in the third quarter. Janiczek Wealth Management LLC now owns 582 shares of the medical research company's stock valued at $40,000 after buying an additional 303 shares during the period. Institutional investors and hedge funds own 79.46% of the company's stock.

Insider Transactions at Edwards Lifesciences

In related news, VP Jean-Luc M. Lemercier sold 14,400 shares of the business's stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $92.32, for a total transaction of $1,329,408.00. Following the transaction, the vice president now directly owns 173,849 shares in the company, valued at $16,049,739.68. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, CFO Scott B. Ullem sold 7,255 shares of the business's stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $78.29, for a total transaction of $567,993.95. Following the transaction, the chief financial officer now directly owns 19,248 shares in the company, valued at $1,506,925.92. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of the business's stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $92.32, for a total transaction of $1,329,408.00. Following the transaction, the vice president now owns 173,849 shares in the company, valued at $16,049,739.68. The disclosure for this sale can be found here. Insiders sold a total of 194,004 shares of company stock valued at $17,166,254 over the last three months. Corporate insiders own 1.29% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on EW shares. Morgan Stanley boosted their target price on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the company an "overweight" rating in a report on Thursday, March 21st. Citigroup boosted their target price on shares of Edwards Lifesciences from $90.00 to $98.00 and gave the company a "neutral" rating in a report on Wednesday, April 3rd. Bank of America upgraded shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating in a report on Thursday, March 7th. OTR Global raised shares of Edwards Lifesciences from a "mixed" rating to a "positive" rating in a research note on Tuesday, March 26th. Finally, Mizuho lifted their price target on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the company a "buy" rating in a research note on Thursday, April 11th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of "Moderate Buy" and a consensus target price of $91.73.

Edwards Lifesciences Stock Down 0.6 %

Shares of NYSE:EW traded down $0.51 during midday trading on Friday, hitting $85.94. 3,870,469 shares of the company's stock were exchanged, compared to its average volume of 3,865,638. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.38 and a quick ratio of 2.40. The stock has a 50 day moving average price of $90.15 and a 200-day moving average price of $78.31. The company has a market cap of $51.73 billion, a PE ratio of 37.37, a price-to-earnings-growth ratio of 4.32 and a beta of 1.05. Edwards Lifesciences Co. has a 12 month low of $60.57 and a 12 month high of $96.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Tuesday, February 6th. The medical research company reported $0.64 EPS for the quarter, hitting the consensus estimate of $0.64. The company had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.50 billion. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The firm's revenue for the quarter was up 13.3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.64 earnings per share. On average, sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.76 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.